Richter in deal to distribute fertility drug in EU-27
Hungarian pharmaceutical firm Gedeon Richter said Tuesday it has signed a license and distribution agreement with U.K.-based L.D. Collins to commercialize the latterʼs assisted reproductive technology (ART) product Cyclogest in 27 EU countries, with the productʼs launch expected in early 2019.
Marketing authorizations have already been granted in the relevant territory, according to a press release sent to the Budapest Business Journal. According to the agreement, Richter will be obligated to pay sales-related royalties to L.D. Collins after the productʼs launch.
"Cyclogest is considered a useful addition to our existing fertility portfolio," said Gábor Orbán, CEO of Gedeon Richter. "Being a responsible player in the pharmaceutical universe, we are aware of the importance of the productiveness of the female population and we are committed to addressing women’s needs."
Cyclogest pessaries contain 400 mg of progesterone, which is a naturally occurring progestogen. The pessaries prepare the lining of the uterus to be as receptive as possible to the embryo and are therefore critical in supporting the luteal phase as part of assisted reproductive technology, according to the press release.
SUPPORT THE BUDAPEST BUSINESS JOURNAL
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.